Cannabinoids in multiple sclerosis: urgent need for long term trials

Por Killestein, J, Uitdehaag, B
Publicado em 2005

Anti‐myelin antibodies in multiple sclerosis: clinically useful?

Por Polman, C H, Killestein, J
Publicado em 2006

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

Por Killestein, J., Vennegoor, A., van Golde, A. E. L., Bourez, R. L. J. H., Wijlens, M. L. B., Wattjes, M. P.
Publicado no Case Rep Neurol Med (2014)

Information processing speed in multiple sclerosis: Relevance of default mode network dynamics

Por van Geest, Q., Douw, L., van 't Klooster, S., Leurs, C.E., Genova, H.M., Wylie, G.R., Steenwijk, M.D., Killestein, J., Geurts, J.J.G., Hulst, H.E.
Publicado no Neuroimage Clin (2018)